|Articles|April 20, 2017

Trending News Today: The Challenge of Post-Surgery Pain Relief Among Former Opioid Addicts

Top news of the day from across the healthcare landscape.

Pharmaceutical manufacturers and other healthcare stakeholders spent more than $2 million on events and contributions to the Trump administration. President Donald Trump’s inaugural committee was found to have raised more than $107 million—more than twice the amount of former President Barack Obama’s committee, which held the record at $53 million, according to Kaiser Health News. The authors of the article speculate that the high amount of spending may be the result of Trump vowing to reduce drug costs and allow the negotiation of Medicare drug costs.

A new study shows that aging mice brains may be rejuvenated by a protein found in umbilical cord blood. When older mice were injected with the protein, an inhibitor of metalloproteinases 2, dormant genes awoke and hippocampal activity increased, according to The Los Angeles Time. The mice were found to have a better performance with memory and learning tasks. The authors believe that these findings may translate to humans.

Post-surgical treatment for patients who previously received treatment for prescription or opioid misuse disorder has proven difficult, according to NPR. Healthcare providers may not be able to determine the best course of action to anesthetize patients or manage pain post-surgery for those with former drug misuse disorders, which could lead to relapse and overdose. Accessing addiction specialists after surgery may mitigate some risks associated with pain management among these patients, according to the article.


Related to this article

Could Litifilimab Offer Faster Relief for Hard-to-Treat Cutaneous Lupus?
In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.